Sulzer to sell its $323 million electrophysiology business
This article was originally published in Clinica
Sulzer Medica is to divest its electrophysiology business, which, at $323 million, represents one-third of Sulzer's Medica total sales, to concentrate on its orthopaedics and cardiovascular prostheses businesses. Both Sulzer Medica and parent company Sulzer's shares hit a year's high on the news.
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.